|
Canada-0-MATTRESSES företaget Kataloger
|
Företag Nyheter:
- label - Food and Drug Administration
Cytarabine Injection, an antineoplastic, is a sterile solution of cytarabine for intravenous, intrathecal or subcutaneous administration Each mL contains 20 mg Cytarabine (20 mg mL) in a
- Cytarabine Injection BP - Pfizer
Cytarabine Injection BP is a clear, colourless or pale-yellow, sterile, isotonic, preservative-free solution containing Cytarabine IP 100 mg in 5 ml, 1000 mg in 10 ml
- Cytarabine: Package Insert Prescribing Information
Cytarabine package insert prescribing information for healthcare professionals Includes: indications, dosage, adverse reactions and pharmacology
- Cytarabine - ASHP
Two combinations were tested: (1) cytarabine 50 mg, methotrexate 12 mg (as the sodium salt), and hydrocortisone 25 mg (as the sodium succi-nate salt); and (2) cytarabine 30 mg, methotrexate 12 mg (as the sodium salt), and hydrocortisone 15 mg (as the sodium succi-nate salt)
- DailyMed - CYTARABINE injection, solution
Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients
- DEPOCYT (cytarabine liposome injection) Label
DepoCyt® (cytarabine liposome injection) is indicated for the intrathecal treatment of lymphomatous meningitis DepoCyt is a cytotoxic anticancer drug and, as with other potentially toxic
- FDA Label for Cytarabine Injection, Solution Intrathecal; Intravenous . . .
The following Structured Product Label (SPL) was submitted to the FDA by Hospira, Inc for the product Cytarabine (NDC 61703-305) This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients
- Cytarabine - Pfizer
Tissues with a high susceptibility have high levels of the activating enzyme Cytarabine has no effect on non-proliferating cells, or on proliferating cells unless in the S or DNA synthesis phase Thus, cytarabine is a cell cycle phase-specific antineoplastic drug
- label - Food and Drug Administration
Cytarabine is a cell cycle phase-specific antineoplastic agent, affecting cells only during the S-phase of cell division Intracellularly, cytarabine is converted into cytarabine-5-triphosphate
- Cytarabine Injection - Pfizer
Cytarabine Injection, an antineoplastic agent, is a sterile preserved solution for intravenous or subcutaneous administration and is available in 20 mg mL (500 mg 25 mL) multiple-dose vial Each mL contains: 20 mg Cytarabine, USP and the following inactive ingredients: benzyl alcohol 0 9% and Water for Injection q s
|
|